CryoLife (CRY) Stock Price, News & Analysis

Company Overview

CryoLife, Inc. engages in the manufacture, process and distribution of medical devices and implantable human tissues. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes revenues from sales of BioGlue products, aortic stents and stent grafts, On-X products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment focuses on revenues from preservation of cardiac and vascular implantable human tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $17.19 to $21.72
• 52-Week Range: N/A
• Volume: 7,792 shs
• Average Volume: 198,221 shs
• Market Capitalization: $703.22 million
• P/E Ratio: 596.20
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CryoLife Stock Analysis - MarketRank™

CryoLife scored higher than 32% of companies evaluated by MarketBeat, and ranked 844th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CryoLife.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 600.00%

Earnings Growth

Earnings for CryoLife are expected to grow by 600.00% in the coming year, from $0.03 to $0.21 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CryoLife is 596.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 130.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of CryoLife is 596.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 136.95.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CRY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CryoLife does not currently pay a dividend.

Dividend Growth

CryoLife does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -1.53

Short Interest

There is no current short interest data available for CRY.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for CryoLife this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for CRY on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CryoLife insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.50% of the stock of CryoLife is held by insiders.

Percentage Held by Institutions

81.57% of the stock of CryoLife is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRY Stock Analysis - Frequently Asked Questions

How were CryoLife's earnings last quarter?

CryoLife, Inc. (NYSE:CRY) issued its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of $0.04 by $0.22. The medical equipment provider earned $72.21 million during the quarter, compared to analyst estimates of $72.90 million. CryoLife had a net margin of 0.63% and a trailing twelve-month return on equity of 4.24%.

Does CryoLife have any subsidiaries?

The following companies are subsidiaries of CryoLife: JOTEC AG, On-X Life Technologies Inc., Hemosphere, Cardiogenesis Corporation, AuraZyme Pharmaceuticals Inc., CryoLife Asia Pacific PTE. Ltd., CryoLife Canada Inc., and others.

What other stocks do shareholders of CryoLife own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CryoLife investors own include Energy Transfer (ET), AT&T (T), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Enterprise Products Partners (EPD), Gilead Sciences (GILD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 10/01/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:CRY
• CUSIP: 22890310
• CIK: 784199
• Web: www.cryolife.com
• Phone: (770) 419-3355
• Fax: 770-426-0031
• Employees: 1,200
• Year Founded: 1984

Profitability

• EPS (Most Recent Fiscal Year): $0.03
• Trailing P/E Ratio: 596.20
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,680,000.00
• Net Margins: 0.63%
• Pretax Margin: 0.41%
• Return on Equity: 4.24%
• Return on Assets: 1.63%

Debt

• Debt-to-Equity Ratio: 0.99
• Current Ratio: 4.21
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $253.23 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 23.30
• Book Value: $8.46 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 39,330,000
• Free Float: 37,560,000
• Market Cap: $703.22 million
• Optionable: Optionable
• Beta: 1.53